Removal of US Securities Law Restrictions, Renalytix AI PLC, 2020-05-05

RNS Number : 9654L
Renalytix AI PLC
05 May 2020


Renalytix AI plc

(“RenalytixAI”, the “Company”)


Removal of US Securities Law Restrictions on Ordinary Shares


Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law on all ordinary shares of £0.0025 each in the capital of the Company (“Ordinary Shares“).  Details of these restrictions were set out in Part 12 of the Company’s admission document dated 5 November 2018 and in the Company’s announcement dated 23 July 2019 relating to a placing of Ordinary Shares.


The Company’s registrar, Link Asset Services, will remove the “REG S” marker on Ordinary Shares held in the CREST system on or around the date of this announcement.  From such time, the Ordinary Shares will not have any restrictive legends applied in the CREST system.  The ISIN (GB00BYWL4Y04) and SEDOL code (BYWL4Y0) of the Ordinary Shares will remain unchanged.


Certificates for Ordinary Shares held in certificated form will not be reissued.  Current share certificates for Ordinary Shares will remain valid and the restrictive legend appearing on the certificates will no longer be relevant.  Any new share certificates issued by the Company will not contain the restrictive legend.


Holders of Ordinary Shares do not need to take any action in this regard.  However, if a holder of Ordinary Shares would like to exchange his or her existing share certificate for a new share certificate without the restrictive legend, the existing share certificate should be sent by post to Link Asset Services at 34 Beckenham Road, Beckenham, Kent BR3 4TU, along with a corresponding request for a new share certificate without the restrictive legend.  Link Asset Services will charge a fee for issuing a new share certificate in accordance with its usual procedures.



For further information, please contact:


Renalytix AI plc

O. James Sterling, Chief Financial Officer

Via Walbrook PR



Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison




N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)


Tom Salvesen (Corporate Broking)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303




About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.




About RenalytixAI

RenalytixAI is a developer of clinical grade, artificial intelligence-enabled in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, and patient stratification for drug clinical trials. For more information, visit


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit




Leave a Reply

Your email address will not be published.